PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
NanoViricides, Inc., reports on independent research highlighting NV-387's broad-spectrum action in viral therapy, potentially revolutionizing antiviral treatment strategies -
-
-
PRESS RELEASE
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
NanoViricides, Inc. showcases strong safety and effectiveness of lead drug NV-387 against coronaviruses, potentially filling the gap in COVID treatments. Seeking collaborations for regulatory approvals -
-
-
PRESS RELEASE
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
NanoViricides, Inc. discusses development program for antiviral drug NV-387 effective against various respiratory infections, advancing towards human clinical trials
